OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 1,390 Shares of argenx SE (NASDAQ:ARGX)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in argenx SE (NASDAQ:ARGX) by 69.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 610 shares of the company’s stock after selling 1,390 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in argenx were worth $375,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of ARGX. Assenagon Asset Management S.A. raised its holdings in shares of argenx by 21.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 34,955 shares of the company’s stock worth $21,497,000 after acquiring an additional 6,161 shares during the period. Park Avenue Securities LLC increased its holdings in argenx by 40.0% during the 4th quarter. Park Avenue Securities LLC now owns 1,695 shares of the company’s stock worth $1,042,000 after purchasing an additional 484 shares in the last quarter. Ritholtz Wealth Management increased its holdings in argenx by 85.5% during the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company’s stock worth $552,000 after purchasing an additional 414 shares in the last quarter. Aaron Wealth Advisors LLC raised its stake in shares of argenx by 10.1% in the 4th quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $301,000 after purchasing an additional 45 shares during the period. Finally, Ballentine Partners LLC lifted its holdings in shares of argenx by 21.5% in the fourth quarter. Ballentine Partners LLC now owns 536 shares of the company’s stock valued at $330,000 after purchasing an additional 95 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Price Performance

argenx stock opened at $542.47 on Wednesday. The company’s 50-day moving average is $593.35 and its 200-day moving average is $613.35. The firm has a market capitalization of $33.12 billion, a PE ratio of -616.44 and a beta of 0.57. argenx SE has a fifty-two week low of $352.77 and a fifty-two week high of $678.21.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.32 by $0.26. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, analysts expect that argenx SE will post 3.13 EPS for the current year.

Wall Street Analyst Weigh In

ARGX has been the subject of several recent research reports. Sanford C. Bernstein raised argenx from a “market perform” rating to an “outperform” rating in a research report on Monday, March 17th. JMP Securities upped their price target on argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research report on Tuesday, January 14th. Robert W. Baird raised shares of argenx from a “neutral” rating to an “outperform” rating and set a $680.00 price target for the company in a research note on Tuesday. Oppenheimer lifted their price objective on shares of argenx from $704.00 to $708.00 and gave the company an “outperform” rating in a report on Friday, May 9th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a “sell” rating to a “hold” rating in a report on Wednesday, March 12th. Two investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $697.94.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.